Aileron Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Enrollment completed in the dose optimization part of the ongoing Phase 1b/2 clinical trial of ALRN-6924 as a chemoprotection agent in cancer patients
- - -
Scheduled to report interim results from the dose optimization part of the Phase 1b/2 trial 2^nd Quarter 2020, and planning final data readout in the fourth quarter of 2020
- - -
Company implemented measures to reduce operating expenses to extend its cash runway to first quarter 2021
- - -

WATERTOWN, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today reported business highlights and financial results for the first quarter ended March 31, 2020.

“We continue to advance ALRN-6924 as a chemoprotection agent for cancer patients, even as the world continues to face the ongoing coronavirus pandemic. We are extremely grateful to our clinical trial sites, and our investigators and their teams for enabling this progress under such difficult circumstances. We have completed enrollment in the third and final cohort of the dose optimization part of our Phase 1b/2 clinical trial in which we are treating small cell lung cancer patients with ALRN-6924 twenty-four hours before topotecan, a standard of care chemotherapy, to study the impact of ALRN-6924 on chemotherapy toxicities,” said Dr. Manuel Aivado, President and CEO of Aileron Therapeutics. “We look forward to announcing interim data from the dose optimization part of the study in the 2^nd quarter of this year.”

ALRN-6924 as a chemoprotection agent

The Company recently completed enrollment in the dose optimization part of its Phase 1b/2 clinical trial evaluating ALRN-6924 as an agent to protect patients with small cell lung cancer (SCLC) against chemotherapy-induced toxicity, a concept known as chemoprotection (or myelopreservation). The Phase 1b part of the study is designed to identify a dose and a schedule of ALRN-6924 administration to reduce chemotherapy toxicities such as severe anemia and thrombocytopenia resulting from topotecan. In this part of the trial, topotecan is administered daily on days 1 through 5 of every 21-day treatment cycle and ALRN-6924 is administered 24 hours before each dose of topotecan (on days 0 through 4 every 21 days). The dose optimization part of the study includes three patient cohorts, one for each dose level, and enrolled a total of 17 patients.